Last updated: July 23, 2026
Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Ltd., No. 1:23-cv-18420, is a Hatch-Waxman patent infringement dispute filed in the District of New Jersey in 2023. The case posture turns on an alleged FDA-led generic or biosimilar entry trigger, with infringement theories and defenses determined by the asserted Orange Book patents and the Paragraph IV/Section viii marketing authorization facts. The dispute’s practical risk for a launch strategy is shaped by (i) what Orange Book listings were asserted, (ii) whether the case qualifies for the automatic stay or only eligibility for a litigation-driven injunction, and (iii) whether Annora obtained any Delaware or E.D. Texas precedents on claim construction or invalidity that survive appeal.
What is the litigation background for Azurity v. Annora (1:23-cv-18420)?
The docket style indicates a conventional Hatch-Waxman posture: a branded pharma plaintiff alleging infringement of one or more Orange Book-listed patents tied to an FDA-approved drug, and a generic defendant tied to an ANDA route or another Hatch-Waxman regulatory trigger (often Paragraph IV). The case is in the District of New Jersey, a common forum for pharmaceutical IP disputes.
Where and when was the case filed?
- Court: U.S. District Court, District of New Jersey (D.N.J.)
- Case number: 1:23-cv-18420
- Caption: Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Ltd.
What type of claims does this case likely involve?
Because the case name and docket number reflect Hatch-Waxman litigation, the operative pleading typically includes:
- Patent infringement claims under 35 U.S.C. § 271 tied to FDA marketing authorization
- Validity challenges by the ANDA filer or generic defendant (invalidity, noninfringement, lack of statutory coverage)
- Declaratory judgment or counterclaims in line with the alleged FDA certification and offer-to-carveout structure
What is the typical relief sought?
In these disputes, plaintiffs usually seek:
- Injunctive relief to block FDA approval and/or market launch
- Damages to the extent the defendant launched or commercially exploited during litigation exposure
What patents were asserted by Azurity in 1:23-cv-18420?
No asserted-patent numbers, Orange Book listings, or claims-in-suit are provided in the prompt. Without the asserted list and the claim charts or complaint sections, a complete and accurate litigation summary that maps infringement theories to specific patent estates cannot be produced.
What is the procedural posture and key motion practice in 1:23-cv-18420?
No docket events, motions, or orders are provided in the prompt. A litigation analysis that identifies summary judgment status, claim construction rulings, stay events, or trial scheduling cannot be produced accurately without the underlying docket text and order entries.
How does the FDA regulatory posture affect litigation risk in Azurity v. Annora?
Hatch-Waxman litigation outcomes depend heavily on what the defendant filed with FDA and how that filing maps to the Orange Book.
What is the case impact if the defendant filed an ANDA with Paragraph IV?
If Annora’s FDA submission included a Paragraph IV certification to the asserted Orange Book patents, the litigation generally determines:
- Whether the plaintiff can secure an injunction based on infringement and non-invalidity findings
- Whether the court resolves invalidity theories under obviousness, anticipation, or statutory bars
What is the case impact if no Paragraph IV trigger exists?
If the submission was not Paragraph IV as to the asserted patents, the litigation framework can still proceed under infringement theories, but the commercial timing implications differ from the typical Paragraph IV stay/jurisdiction patterns.
What is the infringement and invalidity framework used in Hatch-Waxman cases like this?
Without the actual asserted claims and the product description, only the general analytic framework can be stated.
Infringement analysis typically turns on:
- Whether Annora’s proposed product meets the asserted claim limitations (composition, dose, route, formulation, or method-of-use elements)
- Whether labeling carveouts or section viii changes avoid the specific method-of-use trigger (common in use-code disputes)
Invalidity analysis typically turns on:
- Anticipation (single reference)
- Obviousness (combinations)
- Indefiniteness or written description/enablement
- Non-statutory subject matter arguments in the rare case that mechanism claims are asserted
What is the settlement risk profile in this type of case?
In Hatch-Waxman, settlement risk is driven by:
- Strength of the asserted claims in the specific court
- Workability of an early injunction or early validity ruling
- The time to final judgment relative to FDA approval and launch economics
No settlement or negotiation filings are provided in the prompt, so settlement outcomes cannot be summarized.
What injunction or launch outcomes could follow for Annora?
The launch pathway depends on:
- Whether an injunction issues
- Whether the injunction is limited to specific patents or claims
- Whether appellate stays apply and what the FDA does during pendency
No claim results, court orders, or injunction status are provided, so outcomes cannot be stated.
How strong is the patent estate for Azurity’s product in 1:23-cv-18420?
A strength assessment requires:
- Patent numbers and assignees
- Expiration, exclusivity, and prosecution history
- The asserted claim construction posture
No patent identifiers are provided in the prompt, so an estate-strength analysis cannot be produced.
Key litigation takeaways for R&D, licensing, or investment
- The case is filed in the District of New Jersey and is consistent with a Hatch-Waxman infringement dispute, but the prompt does not include the asserted-patent set, filing certifications, or docket outcomes.
- Litigation leverage for either side depends on the asserted Orange Book patents and the court’s ruling on infringement and validity.
- Commercial risk for a defendant typically hinges on whether the court grants injunctive relief on any asserted patent and whether the injunction is stayed pending appeal.
Key Takeaways
- Case: Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Ltd., 1:23-cv-18420 (D.N.J.).
- What can be concluded from the prompt: Only the case identity and forum can be stated.
- What cannot be concluded from the prompt: Asserted patents, claim scope, motion posture, claim construction, validity/infringement findings, injunction status, settlement terms, and launch implications.
FAQs
-
What court has jurisdiction over Azurity v. Annora (1:23-cv-18420)?
District of New Jersey.
-
What statute typically governs patent infringement in Hatch-Waxman cases like this?
35 U.S.C. § 271.
-
What typically determines whether a generic launch is blocked after Paragraph IV litigation?
Court findings on infringement and validity for the asserted Orange Book patents and whether an injunction issues.
-
What information usually shows the asserted patents in this type of case?
The complaint’s “Patents-in-Suit” section and the Orange Book listings it references.
-
What procedural event often drives settlement in pharmaceutical Hatch-Waxman disputes?
Early claim construction and summary judgment rulings that clarify infringement and validity.
References
- U.S. District Court, District of New Jersey, Azurity Pharmaceuticals, Inc. v. Annora Pharma Private Ltd., No. 1:23-cv-18420 (filed 2023).
